Peter Hillmen
University of Leeds
H-index: 95
Europe-United Kingdom
Top articles of Peter Hillmen
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and post-marketing settings | Research and Practice in Thrombosis and Haemostasis | Richard J Kelly Hisakazu Nishimori Regina Horneff Peter Hillmen Mohammed Al-Adhami | 2024/4/24 |
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline | British Journal of Haematology | Austin Kulasekararaj Jamie Cavenagh Inderjeet Dokal Theodora Foukaneli Shreyans Gandhi | 2024/1/21 |
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment | Jennifer R Brown Barbara Eichhorst Peter Hillmen Wojciech Jurczak Maciej Kaźmierczak | 2024/4/1 | |
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del (17p) chronic lymphocytic leukemia | Blood Advances | Stephan Stilgenbauer Eugen Tausch Andrew W Roberts Matthew S Davids Barbara Eichhorst | 2024/2/1 |
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply | New England Journal of Medicine | Talha Munir David A Cairns Adrian Bloor David Allsup Kate Cwynarski | 2024/1/25 |
P786: THROMBOSIS AND MENINGOCOCCAL INFECTION RATES IN PEGCETACOPLAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE CLINICAL TRIAL AND POST-MARKETING SETTINGS | HemaSphere | Richard Kelly Hisakazu Nishimori Regina Horneff Peter Hillmen Jessica Savage | 2023/8/1 |
Telomere Length and DNA Methylation Epitype Both Provide Independent Prognostic Information in CLL Patients; Data from the UK CLL4, Arctic and Admire Clinical Trials | Blood | Louise J Carr Kevin Norris Helen Parker Anna Nilsson-Takeuchi Dean J Bryant | 2023/11/28 |
Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria | Future Rare Diseases | Morag Griffin Jeff Szer Ilene Weitz Alexander Röth Britta Höchsmann | 2023/7/23 |
Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape … | The Lancet Oncology | Peter Hillmen Alexandra Pitchford Adrian Bloor Angus Broom Moya Young | 2023/5/1 |
Efficacy of Coxsackievirus A21 against drug-resistant neoplastic B cells | Molecular Therapy-Oncolytics | Matthew Holmes Gina B Scott Samuel Heaton Tyler Barr Basem Askar | 2023/6/15 |
Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict< 0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment … | Blood | Andy Rawstron Nichola Webster Surita Dalal Ruth M de Tute Sue Bell | 2023/11/28 |
Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI … | Blood | Peter Hillmen David Allan Cairns Adrian John Clifton Bloor David Allsup Kate Cwynarski | 2023/11/28 |
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial | Journal of Clinical Oncology | Peter Hillmen Barbara Eichhorst Jennifer R Brown Nicole Lamanna Susan M O'Brien | 2023/2/2 |
Paroxysmal Nocturnal Haemoglobinuria (PNH) Arising from Non-Canonical Mutations | Blood | Alexandra Pike Stephen John Richards Claire E McKinley Louise M Arnold Abraham Mullasseril Varghese | 2023/11/28 |
Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years | Blood | Carlos M de Castro Brian Mulherin Christopher J Patriquin Veena Selvaratnam Raymond SM Wong | 2023/11/28 |
Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia | New England Journal of Medicine | Jennifer R Brown Barbara Eichhorst Peter Hillmen Wojciech Jurczak Maciej Kaźmierczak | 2023/1/26 |
Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients | Blood | Anita Sarma Charlotte Evans Surita Dalal Nichola Webster Andy Rawstron | 2023/11/28 |
Sars-Cov-2 Antibody and T-Cell Responses in Patients with Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia after Four COVID-19 Vaccinations | Blood | Alexandra Pike Natalie Fox Claire E McKinley Louise M Arnold Mark Harland | 2023/11/28 |
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small … | Blood | Jennifer R Brown Barbara Eichhorst Peter Hillmen Nicole Lamanna Susan M O'Brien | 2022/12/6 |
Abstract CT532: Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic … | Cancer Research | Wojciech Jurczak Nagah Elmusharaf Christopher P Fox William Townsend Amanda G Paulovich | 2022/6/15 |
